PRAX

Praxis Precision Medicines' stock price has experienced significant movement in the past year, with an increase of 435.43% between September 26, 2025, and September 25, 2026, though it has recently shown declines, falling 10.43% in the week leading up to October 11, 2026, and 26.34% over the month. On October 5, 2026, shares fell 5.1% to approximately $280.33. Key events impacting the stock price in the past six months include the U.S. Food and Drug Administration (FDA) extending the review period for the New Drug Application (NDA) for relutrigine, moving the PDUFA target action date from September 27, 2026, to December 27, 2026, following a major amendment submission. The company held its First Quarter 2026 Financial Results Conference Call on May 7, 2026, and its Second Quarter 2026 Financial Results Conference Call on August 6, 2026, reporting a quarterly EPS of -$2.87, which beat expectations of -$3.67. Praxis also participated in several healthcare conferences, including the Bank of America Securities Health Care Conference on May 12, 2026, the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, and the Baird 2026 Global Healthcare Conference on September 15, 2026.